DrugBiological
Bezlotoxumab clinical trials
Also written MK-6072 and Zinplava.
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 7
Merck Sharp & Dohme LLC (3) · Hellenic Institute for the Study of Sepsis (1) · Brigham and Women's Hospital (1) · Ohio State University (1) · David Binion, MD (1) · Montefiore Medical Center (1) · The Cooper Health System (1) · Leiden University Medical Center (1)
Often tested with
Tested in the same studies.
MK-3415A (2) · Actoxumab (1)
Studies
Open first, then newest update. How each study uses bezlotoxumab is read from its arms, and is right about nine times in ten.
Testing it · 10
- Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.TerminatedPhase 4Ohio State UniversityNCT03756454Written as Bezlotoxumab
- Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile InfectionCompletedPhase 2Hellenic Institute for the Study of SepsisNCT05304715Written as Bezlotoxumab
- ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDICompletedPhase 2Brigham and Women's HospitalNCT03829475Written as Bezlotoxumab
- Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).TerminatedPhase 4David Binion, MDNCT04626947Written as Bezlotoxumab
- Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)CompletedPhase 3Merck Sharp & Dohme LLCNCT03182907Written as Bezlotoxumab
- Bezlotoxumab Versus FMT for Multiple Recurrent CDIWithdrawnPhase 4Leiden University Medical CenterNCT05077085Written as Bezlotoxumab
- Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.TerminatedPhase 4Montefiore Medical CenterNCT03937999Written as Bezlotoxumab
- Bezlotoxumab Efficacy and Tolerability in Cancer PatientStatus unknownPhase 4The Cooper Health SystemNCT04415918Written as Bezlotoxumab Injection
- A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)CompletedPhase 3Merck Sharp & Dohme LLCNCT01513239Written as MK-6072
- A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)CompletedPhase 3Merck Sharp & Dohme LLCNCT01241552Written as MK-6072
As the comparator · 1 — what is tested is compared with bezlotoxumab
Codes
What other systems call bezlotoxumab · ClinicalTrials.gg INT000596
- MeSH (NLM) C000613978bezlotoxumabOne source NLM
- UNII (FDA) 4H5YMK1H2EBEZLOTOXUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1855048Confirmed FDA, Wikidata
- Wikidata Q4900370bezlotoxumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C153084BezlotoxumabOne source FDA
- DrugBank DB13140One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000613978 | bezlotoxumab | One source NLM |
| UNII (FDA) | 4H5YMK1H2E | BEZLOTOXUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1855048 | — | Confirmed FDA, Wikidata |
| Wikidata | Q4900370 | bezlotoxumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C153084 | Bezlotoxumab | One source FDA |
| DrugBank | DB13140 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.